NBIX — Neurocrine Biosciences Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $13.53bn
- $2.86bn
U.S. RESEARCH ROUNDUP-Autozone, State Street, UnitedHealth
U.S. STOCKS ON THE MOVE-Uber, silver miners, Arm
U.S. STOCKS ON THE MOVE-Atea Pharmaceuticals, Adobe, Similarweb
U.S. STOCKS ON THE MOVE-Boeing, gold miners, Oracle
Brief: Neurocrine Biosciences Provides Update On Phase 2 Data For Luvadaxistat In Adults With Cognitive Impairment Associated With Schizophrenia
Neurocrine halts development of schizophrenia drug as trial fails (updated)
Neurocrine Biosciences falls after halting development of schizophrenia drug
Neurocrine's experimental drug misses primary goal in schizophrenia trial
U.S. RESEARCH ROUNDUP- Neurocrine Biosciences, Centerspace, Veeva Systems
Neurocrine falls as investors question schizophrenia drug's trial data
U.S. STOCKS ON THE MOVE-Li Auto, NVIDIA, CrowdStrike
U.S. STOCKS ON THE MOVE-Berkshire Hathaway, Super Micro Computer, Elf Beauty
Neurocrine falls as investors question schizophrenia drug's trial data
Neurocrine falls as investors question schizophrenia drug's trial data
Brief: Neurocrine Biosciences Reports Positive Phase 2 Data For NBI-1117568 In Adults With Schizophrenia
Neurocrine's schizophrenia drug meets main goal in mid-stage study (updated)
Neurocrine's schizophrenia drug meets main goal in mid-stage study
U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals
U.S. STOCKS ON THE MOVE-Qualcomm, Moderna, Hershey